(Q33429255)

1 October 2017

Phase I Study of Panobinostat (LBH589) and Letrozole in Postmenopausal Metastatic Breast Cancer Patients (English)

1 reference

1 October 2017

metastatic breast cancer

1 reference

7

Edith A Perez

1 reference

1 October 2017

5

James N Ingle

1 reference

1 October 2017

6

Matthew P Goetz

1 reference

1 October 2017

4

Donald W Northfelt

1 reference

1 October 2017

Alvaro Moreno-Aspitia

series ordinal

3

object named as

Alvaro Moreno-Aspitia

1 reference

1 October 2017

Winston W Tan

1

1 reference

1 October 2017

Jacob B Allred

series ordinal

2

1 reference

1 October 2017

language of work or name

English

0 references

publication date

17 November 2015

1 reference

1 October 2017

Clinical Breast Cancer

1 reference

1 October 2017

16

1 reference

1 October 2017

2

1 reference

1 October 2017

82-86

1 reference

Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal a

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5567753

Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5567753

A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5567753

A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5567753

Histone deacetylase inhibitor LBH589 reactivates silenced estrogen receptor alpha (ER) gene expression without loss of DNA hypermethylation

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5567753

Anticancer activities of histone deacetylase inhibitors

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5567753

Histone deacetylase inhibitors in cancer therapy: is transcription the primary target?

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5567753

Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5567753

HDAC inhibitors: clinical update and mechanism-based potential.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5567753

A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2'-deoxycytidine.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5567753

Transcriptional activation of estrogen receptor alpha in human breast cancer cells by histone deacetylase inhibition

31 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26774555

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1016/J.CLBC.2015.11.003

1 reference

1 October 2017

1 reference

1 October 2017

1 reference